肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

全周期康复视角下的肝癌相关指南及专家共识解读

2022-01-01 复旦大学附属华山医院康复医学科 中国医刊

肝癌肝脏疾病

原发性肝癌,以下简称肝癌,是指由肝细胞或肝内胆管上皮细胞发生的恶性肿瘤,为我国常见恶性肿瘤之一。

中文标题：

全周期康复视角下的肝癌相关指南及专家共识解读

发布机构：

复旦大学附属华山医院康复医学科

发布日期：

2022-01-01

简要介绍：

原发性肝癌,以下简称肝癌,是指由肝细胞或肝内胆管上皮细胞发生的恶性肿瘤,为我国常见恶性肿瘤之一。据国际癌症研究署公布的最新统计数据显示,2020年全球肝癌新发病例数约为90.6万,死亡病例数约为83.0万,肝癌的发病率和死亡率分别占据总癌症发病率和死亡率的4.7%和8.3%,在所有肿瘤中分别居第6位和第3位[1]。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=全周期康复视角下的肝癌相关指南及专家共识解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d2ea71c0023213ac, title=全周期康复视角下的肝癌相关指南及专家共识解读, enTitle=, guiderFrom=中国医刊, authorId=0, author=, summary=原发性肝癌,以下简称肝癌,是指由肝细胞或肝内胆管上皮细胞发生的恶性肿瘤,为我国常见恶性肿瘤之一。, cover=https://img.medsci.cn/2022115/1642253771832_5579292.png, journalId=0, articlesId=null, associationId=2138, associationName=复旦大学附属华山医院康复医学科, associationIntro=复旦大学附属华山医院康复医学科, copyright=0, guiderPublishedTime=Sat Jan 01 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">原发性肝癌,以下简称肝癌,是指由肝细胞或肝内胆管上皮细胞发生的恶性肿瘤,为我国常见恶性肿瘤之一。据国际癌症研究署公布的最新统计数据显示,2020年全球肝癌新发病例数约为90.6万,死亡病例数约为83.0万,肝癌的发病率和死亡率分别占据总癌症发病率和死亡率的4.7%和8.3%,在所有肿瘤中分别居第6位和第3位</span><sup style="color: #333333;">[1]</sup><span style="color: #333333;">。&nbsp;</span></p>, tagList=[TagDto(tagId=429, tagName=肝癌), TagDto(tagId=6634, tagName=肝脏疾病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5136, appHits=101, showAppHits=0, pcHits=196, showPcHits=5035, likes=1, shares=17, comments=3, approvalStatus=1, publishedTime=Sat Jan 15 21:30:35 CST 2022, publishedTimeString=2022-01-01, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Jan 15 21:38:17 CST 2022, updatedBy=6415643, updatedName=凯晨, updatedTime=Wed Jan 03 14:24:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=全周期康复视角下的肝癌相关指南及专家共识解读.pdf)])
全周期康复视角下的肝癌相关指南及专家共识解读.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1223009, encodeId=00431223009b0, content=了解了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12816530333, createdName=ms4000001551689929, createdTime=Sat May 28 16:38:53 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184758, encodeId=dde11184e583d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58176394774, createdName=ms2000000159161089, createdTime=Sun Jan 16 09:00:31 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184743, encodeId=c2621184e433e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 16 07:19:31 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
    2022-05-28 ms4000001551689929

    了解了。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1223009, encodeId=00431223009b0, content=了解了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12816530333, createdName=ms4000001551689929, createdTime=Sat May 28 16:38:53 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184758, encodeId=dde11184e583d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58176394774, createdName=ms2000000159161089, createdTime=Sun Jan 16 09:00:31 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184743, encodeId=c2621184e433e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 16 07:19:31 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
    2022-01-16 ms2000000159161089

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1223009, encodeId=00431223009b0, content=了解了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12816530333, createdName=ms4000001551689929, createdTime=Sat May 28 16:38:53 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184758, encodeId=dde11184e583d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58176394774, createdName=ms2000000159161089, createdTime=Sun Jan 16 09:00:31 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184743, encodeId=c2621184e433e, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jan 16 07:19:31 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
    2022-01-16 微探

    学习学习

    0

相关指南

《2021年欧洲肿瘤内科学会肝细胞癌临床实践指南更新》解读

暂未更新 · 2021-08-16

血液标志物用于临床肝细胞癌早期筛查的专家共识

中华预防医学会感染性疾病防控分会 · 2021-09-20

2021 专家共识：肝细胞癌患者接受乐伐替尼治疗的不良事件的管理

国外肿瘤科相关专家小组（统称） · 2021-11-01

中国肝癌早筛策略专家共识

全国多中心前瞻性肝癌极早期预警筛查项目(PreCar)专家组 · 2021-06-29

肝癌转化治疗中国专家共识（2021版）

中国抗癌协会肝癌专业委员会(CSLC,Chinese Society of Liver Cancer) · 2021-06-24

原发性肝癌的分层筛查与监测指南（2020版）

中华预防医学会(CPMA,Chinese Preventive Medicine Association) · 2021-01-27